Briefs

NEW YORK, February 12 (Genomeweb) -- The microarray market, finding fertile fields in drug discovery and development, could grow to $5 billion by the end of the decade, according to a market study announced today by New York based Kalorama Information, a market researcher.

Today, the market is seen as measuring some $500 million a year, based on revenues from companies like Affymetrix, Agilent and others engaged in producing microarrays. However, it is an emerging market, and one that is challenging to accurately measure since it is a mix of home-brew spotting technologies, commercial and open-source informatics with ancillary monies coming from sales of things like the glass slips used to make some microarrays and the emerging services market.

See http://www.genomeweb.com/articles/view.asp?Article=2003212115041